生物医学工程研究院

Lee Lab

Jie Lee Lab

李杰

李杰

副研究员 · 博、硕士生导师
  • 学历：理学博士
  • 专家类别：副研究员，博、硕士生导师
  • 人才计划：云南省“兴滇英才支持计划”青年人才
  • 人才计划：云南省卫健委后备人才
  • 邮箱：lijie@kmmu.edu.cn
  • 通讯地址：云南省昆明市呈贡区雨花街道春融西路1168号
  • 邮编：650500

研究方向

近年来借助生物信息学与分子生物学的研究方法，深入研究与人类复杂疾病相关的 biomarker 识别、cfDNA 液体活检的临床应用及基因多组学的分子机制。通过机器学习技术，构建识别肿瘤病人、区分肿瘤来源及评估复发风险的模型，为泛癌无创早筛、临床监控和个体化精准医疗提供理论、算法及实验基础。

承担科研项目

  1. 云南省科技厅昆明医科大学基础研究联合专项，cfDNA细胞类型特异性染色质开放特征在非小细胞肺癌及其分子亚型识别中的应用研究，2026-06至2029-05，直接经费50万元，主持。
  2. 云南省卫生健康委员会医学后备人才培养计划，2026-01至2028-12，直接经费24万元，主持。
  3. 癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项，2025ZD0545500，基于类人脑的乳腺癌精准预防体系建立和早期干预策略，2025-08至2029-07，直接经费80万元，课题骨干。
  4. 云南省基础研究专项-面上项目（政策支持类），202501CF070023，基于多组学研究识别胰腺癌染色质开放性特征早筛标志物，2025-06至2028-05，直接经费10万元，主持。
  5. 国家自然科学基金委员会，青年科学基金项目，82404091，基于cfDNA动态靶向识别乳腺癌复发风险及分子亚型的技术和应用研究，2025-01至2027-12，直接经费30万元，主持。
  6. 昆明医科大学2024年发展专项，生物信息计算公共平台搭建，J13509，400万元，项目执行人。
  7. 昆明医科大学高层次引进人才，200万元，主持。

研究成果

  1. Li J#, Yang D#, Lv R#, Jin Y#, Wang M#, Chen Y, Pan X, Yang M, Qin X, Gu X, Yang B, Mou Y, Yu L, You D, Li J, Fan K, Li J, He Q, Deng Y, Jiang D*, Chen Y*, Chen C*. Single-cell mapping of extrachromosomal circular DNA architecture and evolution in cutaneous squamous cell carcinoma. Cancer Lett. 2026;218735. doi: 10.1016/j.canlet.2026.218735. PMID: 42457020. (IF=11.8).
  2. Chen Y, Zhao H, Wang L, Li L, Liu R, Jiang Y, Tang P, Li Y, Ni J, Tao D*, Li J*, Peng J*. CLWD: a Chinese histopathology dataset for lung adenocarcinoma subtype classification. Sci Data. 2026 Mar 5;13(1):599. doi: 10.1038/s41597-026-06906-z. PMID: 41786798; PMCID: PMC13079772. (IF=9.8).
  3. Xu C#, Xia P#, Li J#, Lewis KB, Ciombor KK, Wang L, Smith JJ, Beauchamp RD, Chen XS. Discovery and validation of a 10-gene predictive signature for response to adjuvant chemotherapy in stage II and III colon cancer. Cell Rep Med. 2024 Aug 20;5(8):101661. doi: 10.1016/j.xcrm.2024.101661. Epub 2024 Jul 25. PMID: 39059386. (IF=16.9).
  4. Li J#, Chen J#, Sun X#, Yang H#, Sun K, Liu C, Wang Y, Xu M, Ji X, Zhang J, Wu X, Wang A, Fan B, Zhang X, Wu Y, Cui P, Peng J, Zhao Y, Wu W, Yu H, Bu Z, Ji J, Lan X. Uncovering chromatin accessibility and cancer diagnostic potential via cell-free DNA utilization. Sci Bull (Beijing). 2024;69:2987-2992. doi: 10.1016/j.scib.2024.04.013. PMID: 38664094. (IF=20.6).
  5. Li J#, Sun X, Yang H, Chen J, Bu Z, Ji J, Lan X*. Integrated analysis toolkit for dissecting whole-genome-wide features of cell-free DNA. Clin Transl Med. 2023 Mar;13(3):e1212. doi: 10.1002/ctm2.1212. (IF=11.492).
  6. Pang H#, Jiang Y#, Li J#, Wang Y#, Nie M#, Xiao N, Wang S, Song Z, Ji F, Chang Y, Zheng Y, Yao K, Yao L, Li S, Li P, Song L*, Lan X*, Xu Z*, Hu Z*. Aberrant NAD+ metabolism underlies Zika virus-induced microcephaly. Nat Metab. 2021 Aug;3(8):1109-1124. doi: 10.1038/s42255-021-00437-0. Epub 2021 Aug 12. (IF=27.5).
  7. Chen J#, Sun Y#, Li J#, Lyu M#, Yuan L#, Sun J, Chen S, Hu C, Wei Q, Xu Z, Guo T, Cheng X. In-depth metaproteomics analysis of tongue coating for gastric cancer: a multicenter diagnostic research study. Microbiome. 2024 Jan 8;12(1):6. doi: 10.1186/s40168-023-01730-8. PMID: 38191439; PMCID: PMC10773145. (IF=16.837).
  8. Li J#, Wang W#, Xia P#, Wan L#, Zhang L, Yu L, Wang L, Chen X*, Xiao Y*, Xu C*. Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer. Int J Cancer. 2018 Nov 1;143(9):2150-2160. doi: 10.1002/ijc.31573. (IF=7.396).
  9. Jie Li, Xun Lan*. Perspective on new cell-free DNA technologies for early cancer detection. Cancer Biol Med. 2024 Feb;21(2):139-143. doi: 10.20892/j.issn.2095-3941.2023.0159. Epub 2023 Aug 8. (IF=12.4).
  10. Li J#, Xu M#, Peng J#, Wang J, Zhao Y, Wu W, Lan X*. Novel technologies in cfDNA analysis and potential utility in clinic. Chin J Cancer Res. 2021 Dec 31;33(6):708-718. doi: 10.21147/j.issn.1000-9604.2021.06.07. (IF=7).
  11. Li J#,*, Pan X#, Bi Y#, Huang J, Peng J, Bai C*, Hou J*, Chen Y*. Comprehensive multi-omics analysis of tandem duplicator phenotypes in non-small cell lung cancer. Front Med (Lausanne). 2025 Jun 4;12:1556840. doi: 10.3389/fmed.2025.1556840. PMID: 40534701; PMCID: PMC12174438. (IF=3.1).
  12. Jiang Y, He J, He B, Liu L, Wang L, Li H, Li Y, Shi Y, Liu R, Tang P, Li Y, Du J, Peng J*, Li J*, Chen Y*. Assessing large language model for automated diagnosis of benign and malignant lung tumors. Pathol Res Pract. 2026 Jan;277:156306. doi: 10.1016/j.prp.2025.156306. Epub 2025 Nov 25. PMID: 41308357. (IF=3.0).
  13. Zheng Q, Wang L, Zhang Y, Peng J, Hou J, Wang H, Ma Y, Tang P, Li Y, Li H, Chen Y, Li J*, Chen Y*. Immune Microenvironment Characterization and Machine Learning-Guided Identification of Diagnostic Biomarkers for Ulcerative Colitis. J Inflamm Res. 2025 Jul 9;18:8977-8992. doi: 10.2147/JIR.S526325. PMID: 40661186; PMCID: PMC12256701. (IF=4.1).
  14. Chen Y, Zheng Q, Wang H, Tang P, Deng L, Li P, Li H, Hou J, Li J*, Wang L*, Peng J*. Integrating transcriptomics and proteomics to analyze the immune microenvironment of cytomegalovirus-associated ulcerative colitis and identify relevant biomarkers. BioData Min. 2024 Aug 27;17(1):26. doi: 10.1186/s13040-024-00382-0. PMID: 39192288; PMCID: PMC11348729. (IF=4.0).
  15. Xiaolu Zhang, Jingwei Li, Xun Lan*, Jie Li*. Cell-free DNA-associated multi-feature applications in cancer diagnosis and treatment. Clin Transl Discov. 2024;4:e280. doi: 10.1002/ctd2.280. (IF=1.9).
  16. Tian C, Dong Y, Sun X, Xu L, Ma X, Tao Y, Wang F, Zhang H, Li J, Li K, Chen Y, Liu H, Lan X. Integrative scATAC-seq and mtDNA mutation analysis reveals disease-driven regulatory aberrations in AML. Sci Bull (Beijing). 2025 Oct 15;70(19):3215-3232. doi: 10.1016/j.scib.2025.07.009. Epub 2025 Jul 16. PMID: 40781032. (IF=20.6).
  17. Zhu W#, Mou Y#, Yu L#, Fan K#, Chen K, Duan R, Ye J, Huang S*, Li J*, Chen C*. Cell-free DNA analysis for cancer management: Technologies, features, and clinical translation. Mol Digit Med. 2026;1(1):100005. doi: 10.1016/j.mdmed.2026.100005. (IF=暂无).
  18. Liu C#, Zhou Y#, Xu L#, Qin X#, Guan Z, Liu T, Tian C, Li J, Gu F, Lan X*. Deciphering microenvironmental heterogeneity by scalable Niche Guided Module Discovery. Commun Biol. 2026 May 13. doi: 10.1038/s42003-026-10240-w. (IF=5.2).
  19. Ying Yang, Wei Zeng, Xin Wei, Juan Li, Xuelian Chen, Zuyi Zhou, Bo Yang*, Jie Li*, Li Li*. Identification of immune-infiltrated and stroma-enriched subtypes in HER2+ breast cancer. Clin Transl Discov. 2026;6:e70169. doi: 10.1002/ctd2.70169. (IF=1.9).
  20. Xu C#, Qi R#, Ping Y#, Li J, Zhao H, Wang L, Du MY, Xiao Y*, Li X*. Systemically identifying and prioritizing risk lncRNAs through integration of pan-cancer phenotype associations. Oncotarget. 2017 Feb 14;8(7):12041-12051. doi: 10.18632/oncotarget.14510. (IF=暂无).
  21. Xu C#*, Ping Y#, Zhao H#, Ning S, Xia P, Wang W, Wan L, Li J, Zhang L, Yu L, Xiao Y*. LncNetP, a systematical lncRNA prioritization approach based on ceRNA and disease phenotype association assumptions. Oncotarget. 2017 Dec 8;8(68):114603-114612. doi: 10.18632/oncotarget.23059. (IF=暂无).
  22. Wang S#, Xia P#, Zhang L#, Yu L#, Liu H, Meng Q, Liu S, Li J, Song Q, Wu J, Wang W, Yang L*, Xiao Y*, Xu C*. Systematical Identification of Breast Cancer-Related Circular RNA Modules for Deciphering circRNA Functions Based on the Non-Negative Matrix Factorization Algorithm. Int J Mol Sci. 2019 Feb 20;20(4):919. doi: 10.3390/ijms20040919. (IF=4.9).
  23. Wang X, Chen H, Jiang R, Hong X, Peng J, Chen W, Jiang J, Li J, Huang D, Dai H, Wang W, Lu J, Zhao Y, Wu W. Interleukin-17 activates and synergizes with the Notch signaling pathway in the progression of pancreatic ductal adenocarcinoma. Cancer Lett. 2021 Jun 28;508:1-12. doi: 10.1016/j.canlet.2021.03.003. (IF=10.1).